Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (801-810 of 849) with videos related to

Pageof 85
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Journal of Hepatology|April 12, 2020
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementMohammed Eslam, Philip N Newsome, Shiv K Sarin, et al.
Journal of Hepatology|June 23, 2025
Impact of first and further decompensation in patients with compensated ACLD due to MASLDGrazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, et al.
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
Gastroenterology|July 31, 2012
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infectionEtienne Patin, Zoltán Kutalik, Julien Guergnon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
European Journal of Heart Failure|January 14, 2025
Transcatheter edge-to-edge repair in severe mitral regurgitation following acute myocardial infarction - aetiology-based analysisDan Haberman, Rodrigo Estévez-Loureiro, Andrew Czarnecki, et al.
Plos One|November 14, 2023
Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trialTufail Bashir, Marcus Achison, Simon Adamson, et al.
Plos One|October 20, 2023
ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trialChristos Rossios, Tufail Bashir, Marcus Achison, et al.
Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
Pageof 85

Showing results (801-810 of 849) with videos related to

Sort By:
Pageof 85
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Journal of Hepatology|April 12, 2020
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementMohammed Eslam, Philip N Newsome, Shiv K Sarin, et al.
Journal of Hepatology|June 23, 2025
Impact of first and further decompensation in patients with compensated ACLD due to MASLDGrazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, et al.
Gut|January 10, 2024
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver diseaseAngelo Armandi, Tiziana Sanavia, Ramy Younes, et al.
Gastroenterology|July 31, 2012
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infectionEtienne Patin, Zoltán Kutalik, Julien Guergnon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
European Journal of Heart Failure|January 14, 2025
Transcatheter edge-to-edge repair in severe mitral regurgitation following acute myocardial infarction - aetiology-based analysisDan Haberman, Rodrigo Estévez-Loureiro, Andrew Czarnecki, et al.
Plos One|November 14, 2023
Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trialTufail Bashir, Marcus Achison, Simon Adamson, et al.
Plos One|October 20, 2023
ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trialChristos Rossios, Tufail Bashir, Marcus Achison, et al.
Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
Pageof 85